Novus and Golden Grail Technology's AccurateVenture Execute Strategic Partnership Agreement

Novus MedPlan to be Offered to AccurateVenture Customers; AccurateVenture's Hemp Products Now Covered Nationwide Under Novus MedPlan

MIAMI, FL / ACCESSWIRE / March 16, 2017 / Novus Acquisition and Development, Corp. NDEV, through its wholly owned subsidiary WCIG Insurance Services, Inc., is a diversified insurance entity in health, liability, annuity and accident, and the nation's first carrier/aggregator offering a cannabis health plan, today announced a partnership with Golden Grail Technology's AccurateVenture GOGY. Marketing and processing under the Strategic Partnership Agreement is targeted to start in early April 2017.

Novus is proud to announce it has executed a Strategic Partnership Agreement with AccurateVenture, a leading performance-based marketing company. Novus will now cover the bioRenovate ® Pharmaceutical Grade Hemp Cannabidiol products and the consumer Miracle Brand CBD products, under its Novus MedPlan. The Agreement calls for AccurateVenture to offer its approximate 200,000 customers base the opportunity to purchase the Novus MedPlan giving Novus' patient members up to a 50% discount off the purchase of any of AccurateVenture's Cannabidiol products.

Novus MedPlan is the nation's first health plan that focuses on reducing your cost associated with Medical Marijuana and Hemp/CBD (Cannabidiol). This revolutionary service fills the gaps where your insurance policies do not provide coverage or discounts. Novus offers highly affordable plans to people with and without current health insurance. Novus CEO, Frank Labrozzi, stated, "It's exciting to be working with an industry leader with a significant customer base in the cannabis space. There is no doubt AccurateVenture will help to make Novus MedPlan an even more recognized name and allow us to offer it to a much broader client base."

"Novus is clearly out in front of the insurance industry in the cannabis space," stated, AccurateVenture CEO, Bill Fisher. "When I started strategizing back in 2014, I knew one of the most challenging obstacles would be the cost of true pharma-grade product for people without insurance. Novus is an answered prayer for those who use hemp products for health and wellness on a daily basis, and we are excited to get started."

AccurateVenture is currently in the engineering phase of implementing the sales funnel to adopt the Novus sign-ups into its daily process and the program should launch by early April 2017.

About Golden Grail Technology Corp.

Golden Grail Technology Corp. (GOGY) is a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors such as jewelry, health and personal care, beauty, electronics, pet and animal supplies, sports and games. Golden Grail's mission is to utilize their network of industry experts, who specialize in targeting areas of business that can be accelerated with technology, in order to give small companies an opportunity to compete with industry giants.

For more information, please visit: http://goldengrailtechnology.com
And: http://accurateventure.com

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as, health, property & casualty, life, accident and fixed annuities.

Novus medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

• For more information, please visit: http://www.getnovusnow.com
• For NDEV 3rd Quarter Financial Filing: http://bit.ly/2hNHQSg
• Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva

Forward-Looking Statements

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Corporate:
Chairman and CEO
Frank Labrozzi
frank@ndev.biz
855-228-7355

Investors:
Hayden IR
hart@haydenir.com
917-658-7878

SOURCE: Novus Acquisition & Development Corp.